menu
    • menu
    [{"orgOrder":0,"company":"Quotient Sciences","sponsor":"CytoAgents","pharmaFlowCategory":"D","therapeuticArea":"Pharmacology\/Toxicology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"GP1681","moa":"GPCR","graph1":"Pharmacology\/Toxicology","graph2":"Phase I\/ Phase II","graph3":"Quotient Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Quotient Sciences \/ CytoAgents","highestDevelopmentStatusID":"7","companyTruncated":"Quotient Sciences \/ CytoAgents"},{"orgOrder":0,"company":"CytoAgents","sponsor":"TFS Health Science","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CTO1681","moa":"GPCR","graph1":"Pharmacology\/Toxicology","graph2":"Phase I\/ Phase II","graph3":"CytoAgents","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CytoAgents \/ TFS Health Science","highestDevelopmentStatusID":"7","companyTruncated":"CytoAgents \/ TFS Health Science"},{"orgOrder":0,"company":"CytoAgents","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CTO1681","moa":"GPCR","graph1":"Pharmacology\/Toxicology","graph2":"Phase I\/ Phase II","graph3":"CytoAgents","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CytoAgents \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"CytoAgents \/ Inapplicable"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Quotient Sciences

                            United Kingdom
                            CPhI Japan
                            Booth #5P-21
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothQuotient Sciences- Molecule to Cure. Fast.

                            Lead Product(s) : GP1681

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Phase I/ Phase II

                            Sponsor : CytoAgents

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Quotient Sciences and CytoAgents Accelerate Potential Treatment for COVID-19 Cytokine Storm

                            Details : The collaboration aims to focus on the development of GP1681 (CTO1681), which is a small molecule inhibitor of cytokine release targeting the NF-kB signaling pathway via the activation of the EP4 receptor. It is under development for treatment of cytokin...

                            Product Name : GP1681

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            April 28, 2020

                            Lead Product(s) : GP1681

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : CytoAgents

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            Quotient

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            CytoAgents

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            CytoAgents

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CTO1681

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CytoAgents Announces Initiation of Patient Enrollment in Phase 1b/2a Clinical Trial to Treat Cytokine Release ...

                            Details : CTO1681 cell therapy, prevents and treats Cytokine Release Syndrome by targeting the NF-kB signaling pathway via the activation of the EP4 receptor, which reduces NF-kB signaling.

                            Product Name : CTO1681

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 17, 2023

                            Lead Product(s) : CTO1681

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Humanigen

                            U.S.A arrow
                            WRIB
                            Not Confirmed

                            Humanigen

                            U.S.A arrow
                            WRIB
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lenzilumab

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Humanigen Secures U.S. Patent for Lenzilumab in Preventing Cytokine Storm and Neurotoxicity Related to CAR-T C...

                            Details : The patent covers the use of lenzilumab to prevent or treat cytokine release syndrome (CRS), neurotoxicity and otherwise inhibit or reduce incidence or severity of CAR-T-related toxicities in patients undergoing CAR-T cell therapy.

                            Product Name : Humaneered

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            December 28, 2020

                            Lead Product(s) : Lenzilumab

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth